Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

News Daily News

Sudden Cardiac Death in Athletes Is Rare, but Affects Black Population More

Michael O'Riordan

December 06, 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

News Conference News EHRA 2024

Ultralow-Temperature Cryoablation Promising for Monomorphic VT

Todd Neale

April 12, 2024

Presentation ACC 2024

Efficacy and Safety of Ninerafaxstat, a Novel Cardiac Mitotrope, in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (Results of IMPROVE-HCM)

Presenter: Martin S. Maron

April 08, 2024

News Conference News ESC Heart Failure 2023

Could Copper Chelation Benefit HFrEF? TRACER-HF Offers Mixed Clues

Shelley Wood

May 25, 2023

News Conference News ACC 2023

Studies Support (Careful) Return to Sport for Athletes With Genetic Conditions

Michael O'Riordan

March 07, 2023

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Todd Neale

May 31, 2022

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Shelley Wood

April 03, 2022

News Daily News

Young People With Cardiac Conditions Rarely Die From Sex

Michael O'Riordan

January 18, 2022

News Conference News ESC 2020

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

Michael O'Riordan

August 29, 2020

News Conference News HRS 2020

Subcutaneous ICD Holds Up Well Against Transvenous Devices

Todd Neale

May 13, 2020

News Daily News

Survival After Septal Ablation for HOCM Similar to General Population

L.A. McKeown

February 06, 2014

Advertisement

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Sudden Cardiac Death in Athletes Is Rare, but Affects Black Population More

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Ultralow-Temperature Cryoablation Promising for Monomorphic VT

Efficacy and Safety of Ninerafaxstat, a Novel Cardiac Mitotrope, in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (Results of IMPROVE-HCM)

Could Copper Chelation Benefit HFrEF? TRACER-HF Offers Mixed Clues

Studies Support (Careful) Return to Sport for Athletes With Genetic Conditions

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Young People With Cardiac Conditions Rarely Die From Sex

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

Subcutaneous ICD Holds Up Well Against Transvenous Devices

Survival After Septal Ablation for HOCM Similar to General Population

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content